Investigation announced for Investors who lost money with shares of PTC Therapeutics, Inc. (NASDAQ: PTCT)

An investigation was announced for investors of PTC Therapeutics, Inc. (NASDAQ: PTCT) shares over potential securities laws violations by PTC Therapeutics, Inc in connection with certain financial statements.

Investors who purchased shares of PTC Therapeutics, Inc. (NASDAQ: PTCT), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of PTC Therapeutics, Inc. (NASDAQ: PTCT) concerning whether a series of statements by PTC Therapeutics, Inc. (NASDAQ: PTCT regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

South Plainfield, NJ based PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. PTC Therapeutics, Inc. reported that its annual Total Revenue rose from $538.59 million in 2021 to $698.8 million in 2022, and that its Net Loss increased from $523.9 million in 2021 to $551.89 million in 2022.

On September 15, 2023, PTC Therapeutics, Inc. issued a press release "announc[ing] . . . that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a negative opinion on the conversion of the conditional marketing authorization to full marketing authorization of Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). The negative opinion also applies to the renewal of the existing conditional authorization."

Shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) declined from $41.93 per share on September 07, 2023, to as low as $20.17 per share on October 04, 2023.

Those who purchased shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.